Detalhe da pesquisa
1.
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
N Engl J Med
; 375(18): 1738-1748, 2016 11 03.
Artigo
Inglês
| MEDLINE | ID: mdl-27717303
2.
Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial.
Breast Cancer Res Treat
; 167(3): 659-669, 2018 02.
Artigo
Inglês
| MEDLINE | ID: mdl-29058175
3.
Dose Delays, Dose Reductions, and Relative Dose Intensity in Patients With Cancer Who Received Adjuvant or Neoadjuvant Chemotherapy in Community Oncology Practices.
J Natl Compr Canc Netw
; 13(11): 1383-93, 2015 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-26553767
4.
Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study.
Lancet Oncol
; 14(11): 1121-1128, 2013 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-24007746
5.
HER2-positive advanced breast cancer.
Hematol Oncol Clin North Am
; 21(2): 293-302, 2007 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-17512450
6.
Multidisciplinary Management of Locally Advanced Breast Cancer.
Breast J
; 5(5): 303-307, 1999 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-11348306